Evaluation of incretin levels in patients with prolactinoma

Prolactin has been shown to play an important role in the regulation of glucose metabolism. The present study aimed toevaluate incretin hormones in patients with prolactinoma.

The study included 13 patients with prolactinoma without a history of diabetes and in 13 healthy volunteers.All participants underwent a 75-g oral glucose tolerance test (OGTT). Serum glucose, insulin, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured at 0, 30, 60, 90, and 120 minutes.

Serum glucose and insulin levels at baseline and during the OGTT were similar in both groups (p > 0.05). GLP-1 levels, including baseline values, area under the curve (AUC), and all time points during OGTT, were also comparable between the groups (p > 0.05).In contrast, baseline GIP (p = 0.024), AUC (p = 0.011), and GIP levels at 30, 90, and 120 minutes were significantly lower in patients withprolactinoma (p = 0.006, p = 0.015, and p = 0.035, respectively).

These findings suggest that incretins may play a role in the mechanisms underlying glucose metabolism disorders in patientswith hyperprolactinemia due to prolactinoma. Larger studies are needed to confirm this potential association.